A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference

Gynecologic Oncology

Volumn 101, Issue 1, 2006, Pages 4-11

  Palmer, Cheryl ^a   Pratt, Jennie ^a   Basu, Bristi ^a   Earl, Helena ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CA125; Epithelial ovarian cancer; Follow up

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; OVARY CANCER; PATIENT EDUCATION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; DISCLOSURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 33644550004     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.046     Document Type: Article

References (28)

1. R.C. Bast, T.L. Klug, and E. St. John A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N. Engl. J. Med. 309 1983 883 887
2. T.J. O'Brien, J.B. Beard, and L.J. Underwood The CA125 gene: an extracellular superstructure dominated by repeat sequences Tumour Biol. 22 6 2001 (Nov-Dec) 348 366
3. T.J. O'Brien, J.B. Beard, and L.J. Underwood The CA125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure Tumour Biol. 23 3 2002 (May-Jun) 154 169
4. I.J. Jacobs, and U. Menon Progress and challenges in screening for early detection of ovarian cancer Mol. Cell Proteomics 3 4 2004 (Apr) 355 366
5. B.R. Obeidat, Z.O. Amarin, and J.A. Latimer Risk of malignancy index in the preoperative evaluation of pelvic masses Int. J. Gynaecol. Obstet. 85 3 2004 (Jun) 255 258
6. O. Mogensen Prognostic value of CA 125 in advanced ovarian cancer Gynecol. Oncol. 44 1992 207 212
7. C.W.E. Redman, G.R. Blackledge, and K. Kelly Early serum CA 125 response and outcome in epithelial ovarian cancer Eur. J. Cancer 26 1990 593 596
8. J. Fisken, R.C.F. Leonard, and M. Stewart The prognostic value of early CA 125 serum assay in epithelial ovarian cancer Br. J. Cancer 68 1993 140 145
9. I.G. Ron, M. Inbar, and I. Gelernter Use of CA 125 response to predict survival parameters of patients with advanced ovarian carcinoma Acta Obstet. Gynecol. Scand. 73 1994 658 662
10. A. Gadduchi, P. Zola, and F. Landoni Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study Gynecol. Oncol. 58 1995 42 47
11. P.M. Fayers, G.J.S. Rustin, and R. Wood The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer Int. J. Gynecol. Cancer 3 1993 285 292
12. J.L. Wilder, E. Pavlik, and J.M. Straughn Clinical implications of a rising CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation Gynaecol. Oncol. 89 2 2003 233 235
13. K. Eagle, and J.A. Ledermann Tumor markers in ovarian malignancies The Oncologist 2 5 1997 324 329
14. C. Miralles, M. Orea, and P. Espana Cancer antigen 125 associated with multiple benign and malignant pathologies Ann. Surg. Oncol. 10 2 2003 150 154
15. E. McColl Questionnaire design and construction Nurse Res. 1 2 1993 16 25
16. K.M. Schaefer, E.C. Ladd, and S.E. Lammers In your skin you are different: women living with ovarian cancer during childbearing years Qual. Health Res. 9 2 1999 227 242
17. B. Jack, and A. Clarke The purpose and use of questionnaires in research Prof. Nurse 14 3 1998 176 179
18. I. Oppenheim Questionnaire design, interviewing and attitude measurement 1992 Pinter Publications New York, NY
19. D.K. Armstrong Relapsed ovarian cancer: challenges and management strategies for a chronic disease The Oncologist 7 5 2002 20 28
20. M.E.L. van der Burg, F.B. Lammes, and J. Verweij The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer Ann. Oncol. 1 1990 301 302
21. A.E. Guppy, and G.J. Rustin CA125 response: can it replace the traditional response criteria in ovarian cancer? The Oncologist 7 5 2002 437 443
22. G.J. Rustin, A. Nelstrop, and J. Stilwell Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group Eur. J. Cancer 28 1992 79 82
23. G.J.S. Rustin, A.E. Nelstrop, and M.K. Tuxen Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study Ann. Oncol. 7 1996 361 364
24. G.J.S. Rustin, A.E. Nelstrop, and P. McClean Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125 J. Clin. Oncol. 14 1996 1545 1551
25. G.J.S. Rustin, M. Marples, and A.E. Nelstrop Use of CA125 to define progression of ovarian cancer in patients with persistently elevated levels J. Clin. Oncol. 19 2001 4054 4057
26. B. Gronlung, C. Hogdall, and J. Hilden Should CA-125 response criteria be preferred to response evaluation criteria in solid tumours (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J. Clin. Oncol. 22 15 2004 (Oct.) 4051 4058
27. E.A. Eisenhauer, J.B. Vermoken, and M. van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann. Oncol. 8 1997 963 968
28. A. Lofters, H.G. Juffs, and G.R. Pond "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer J. Urol. 168 6 2002 (Dec.) 2516 2520